SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amidst heightened geopolitical tensions, primarily fueled by President Trump's recent rhetoric regarding Greenland and threats of substantial tariffs against European allies like France. The community is bracing for significant market volatility, with many predicting a "bloodbath" and actively discussing bearish positions, while others anticipate a "buy the dip" recovery. These concerns are amplified by broader instability in global financial markets, including surging bond yields in both the US and Japan.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid escalating geopolitical tensions and tariff threats from the US concerning Greenland, compounded by an anticipated Supreme Court decision related to tariffs, which has triggered a pre-market sell-off in tech-heavy indices. Community sentiment is sharply divided; while some anticipate a severe market downturn and "Black Tuesday," many others see this as a manufactured dip and a "buy the dip" opportunity, expecting a quick recovery. This dynamic reflects QQQ's sensitivity to global trade policy and broader economic uncertainties, despite ongoing tech sector narratives.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant buzz following its Saudi FDA approval for non-small cell lung cancer, signaling a potential paradigm shift in cancer treatment. The community is fiercely optimistic, citing high short interest, CEO Dr. Patrick Soon-Shiong's vocal advocacy against perceived FDA bureaucracy, and the company's mission to cure cancer as drivers for an anticipated massive short squeeze and substantial growth.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending strongly, fueled by recent breakthrough pancreatic cancer data and high expectations surrounding its J.P. Morgan Healthcare Conference presentation. The community is abuzz with anticipation for imminent PMDA approval in Japan and rumored institutional buying, spotlighting Alpha Tau's innovative Alpha DaRT technology as a potentially undervalued and disruptive force in oncology. Significant trading volume reflects growing investor confidence and a belief that clinical milestones are poised to drive substantial upside, independent of broader market trends.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is heavily discussed due to its strong pivot towards becoming a major AI cloud infrastructure provider, significantly highlighted by a massive power and infrastructure deal with a prominent tech client. Community sentiment points to high expectations for additional large-scale AI/HPC partnerships, particularly given its substantial power capacity and strategic advantages in the booming compute sector. Investors are actively watching for further developments as the company solidifies its position beyond traditional crypto mining.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors are enthusiastic about recent confirmations of its Optical Interposer technology being utilized by major players like Marvell, acquired through Celestial AI. The community is actively discussing POET's role as a critical enabler for the AI and data center "optical supercycle" by offering high-density, low-power, and cost-effective optical interconnect solutions. Anticipation is high for upcoming customer and investor disclosures, though some perceive market manipulation hindering immediate price appreciation.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is experiencing significant upward momentum driven by strong preliminary Q4 results and an accelerated 2026 outlook, with IBSRELA revenue now projected to reach $1 billion by 2029. This bullish sentiment is further fueled by a patent extension for both IBSRELA and XPHOZAH until 2041, which the community sees as a 'game changer' fundamentally re-rating the company's long-term value and sparking widespread speculation about potential acquisition interest.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to its strategic joint venture for a rare earth processing facility with a major Saudi industrial conglomerate, aiming to secure a mine-to-processing supply chain. The community is actively discussing the geopolitical implications of Greenland's critical mineral assets, viewing CRML as pivotal to Western rare earth independence. This positions the company as a key player in essential resource security, fueling widespread anticipation for future developments.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending amidst a notable downturn, with community discussion centered on a resurfaced short report alleging fraudulent data practices and money laundering. Despite recent analyst upgrades highlighting its strong fundamentals and AI-driven ad platform, many investors are debating whether the sharp decline stems from market manipulation or presents a strategic buying opportunity ahead of upcoming earnings.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending following its Investor Day, where the company announced significantly raised revenue guidance for 2026 and a substantial increase in its backlog, alongside a billion-dollar offering that reflects strong institutional confidence in its strategic defense technology acquisitions. The community is sharply divided, with bulls emphasizing the firm's combat-proven drone and counter-UAS capabilities for future growth, while others express concern over stock volatility and valuation, leading to a mixed market reaction to its updated outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>XTL will acquire NeuroNOS for 19.9% of its issued share capital, $1 million in cash, and milestone-based contingent payments totaling up to $32.5 million. &nbsp;</li><li>NeuroNOS is a biotechnology company eyeing the development of therapeutics for Autism Spectrum Disorder (ASD) and other neurodevelopmental and neurodegenerative disorders.&nbsp;</li><li>NeuroNOS will now serve as XTL's platform for autism and neuro-oncology therapeutics.</li></ul>Shares of Beyond Air, Inc. (XAIR) rallied 149% on Tuesday after XTL Biopharmaceuticals Ltd. (XTLB) announced a deal to acquire a majority stake in its subsidiary NeuroNOS Ltd.Under the deal, IP portfolio company XTL will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.beyondair.net/news-events/press-releases?i=161064">acquire</a> 85% of NeuroNOS, a biotechnology company eyeing the development of therapeutics for Autism Spectrum Disorder (ASD), and other neurodevelopmental and neurodegenerative disorders.Shares of XTLB gained 51% at the time of writing.<h2 class="st-heading-2">Deal Terms</h2>As part of the deal, XTL will acquire 85% of NeuroNOS for 19.9% of XTL's issued share capital, $1 million in cash, and milestone-based contingent payments totaling up to $32.5 million.XTL noted that NeuroNOS's drug development platform is designed to address the underlying molecular mechanisms driving autism unlike treatments based on behavioral symptoms. NeuroNOS will now serve as XTL's platform for autism and neuro-oncology therapeutics.According to BeyondAir, autism spectrum disorder affects about one in 31 children in the U.S. and has been rising dramatically. No FDA-approved therapies aimed at disease modification exist for the disorder at present.The company also noted that the Trump administration has, in recent times, emphasized support for new medicines aimed at treating autism.“The administration has allocated $50 million in new NIH funding for autism research initiatives. This recognition at the federal level signals a fundamental shift in regulatory priorities and resource allocation toward autism research and treatment development,” BeyondAir said in a statement.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around XAIR and XTLB rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user applauded the deal, opining that selling most of the unit will help de-risk Beyond Air’s investment while also creating potential future revenue streams.<stembedurl>https://www.stocktwits.com/stockpro2010/message/641694012</stembedurl><a href="https://stocktwits.com/symbol/XAIR">XAIR stock</a> has fallen 70% this year while <a href="https://stocktwits.com/symbol/XTLB">XTLB</a> dropped 44% in the same period.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/travere-therapeutics-stock-slumps-after-fda-extends-drug-review-timeline-to-april/cmUXhZuR4IK">Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April: Retail Is Divided On Eventual Approval</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

XAIR Stock More Than Doubled Today — What’s Driving The Rally?

Beyond Air said that IP portfolio company XTL will acquire 85% of its subsidiary NeuroNOS.

Equity

Beyond Air said that IP portfolio company XTL will acquire 85% of its subsidiary NeuroNOS.


Beyond Air Names Dan Moorhead CFO

(RTTNews) - Beyond Air, Inc. (XAIR), a commercial-stage medical device and biopharmaceutical company, on Tuesday announced that it has appointed Dan Moorhead as Chief Financial Officer, effective...

Chagee Holdings, Tilray Brands And 3 Stocks To Watch Heading Into Friday

US stock futures higher. Chagee Holdings, Tilray Brands, Globus Maritime, Post Holdings, and Beyond Air in focus.read more...

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates

Beyond Air (XAIR) delivered earnings and revenue surprises of -2.00% and -1.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +29.41% and +146.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Beyond Air (XAIR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates

Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates

Medical device company Beyond Air ($XAIR) stock was down 9.8% on Tuesday morning (9:49 a.m. ET) after the company’s second-quarter revenues fell short of analyst estimates, pushing retail sentiment down.The biopharma company’s earnings per share (EPS) were in line with analyst estimates of -$0.28.However, its revenue came in at $798,000, falling short of consensus estimates of about $1.08 million. Net loss narrowed to $14.3 million compared to $17.4 million in the same period last year.“Our commercial strategy continued to drive results throughout the quarter with our total number of customers increasing by over 60%,” Steve Lisi, CEO of Beyond Air, said in a statement. “We believe this is just the beginning of a pivotal year for our company as we leverage our expanding network of reference customers that have implemented LungFit PH in their hospitals.”Retail sentiment on the stock turned ‘extremely bullish’ from ‘bullish’ a day ago. The accompanying message volumes were in the ‘high’ zone on Tuesday.<figure class="image"><img style="aspect-ratio:1300/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_12_at_8_18_04_PM_25a6267991.png" alt="Screenshot 2024-11-12 at 8.18.04 PM.png" width="1300" height="290"><figcaption>XAIR Sentiment and Message Volume on Nov 12 as of 9:47 a.m. ET | Source: Stocktwits</figcaption></figure>Beyond Air, which is focused on developing treatments for lung diseases, has also completed a $20.6 million private placement offering with “multiple healthcare-focused institutional funds” and company insiders, according to its regulatory filing with the Securities and Exchange Commission (SEC).In addition, it has also retired $17.5 million in debt from Avenue Capital and has entered into a $11.5 million loan agreement with an insider-led investor group. In 2021, Beyond Air reorganized its oncology business into a new private company called Beyond Cancer. Beyond Air’s preclinical oncology team and exclusive rights to the intellectual property portfolio for the treatment of solid tumors are currently with Beyond Cancer.Beyond Air has 80% ownership in Beyond Cancer.Beyond Air’s stock is down 77.2% year-to-date.For updates and corrections, email newsroom@stocktwits.com&nbsp;

The biopharma company’s earnings were in line with analyst estimates of -$0.28 per share.| Source: Pixabay

Beyond Air Stock Slides After Q2 Earnings Beat, Retail’s Confident

Retail sentiment on the stock turned ‘extremely bullish’ from ‘bullish’ a day ago.

Beyond Air ($XAIR), a medical device and biopharmaceutical company focused on developing treatments for lung diseases, saw its shares rise 6% (2:06 pm ET) ahead of its second-quarter earnings, lifting retail sentiment on Stocktwits.The commercial-stage medical device and biopharmaceutical company is expected to report a net loss per share of $0.28 on revenue of $1.03 million by Wall Street analysts. The company beat EPS estimates last quarter by 14.80%, posting a loss per share of $0.27. It has beaten consensus estimates three times in the last four quarters and re-issued revenue guidance of at least $10 million for FY 2025 in August.Retail sentiment on the company inched up on Monday, rising to ‘bullish’ (67/100) from ‘neutral’ (46/100) a day ago as message volumes rose from ‘low’ to ‘high.’<figure class="image"><img style="aspect-ratio:1300/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_12_at_12_39_59_AM_b3e5e1fde4.png" alt="Screenshot 2024-11-12 at 12.39.59 AM.png" width="1300" height="290"><figcaption>XAIR sentiment meter and message volumes on Nov 11 as of 2:08 pm</figcaption></figure>Many Stocktwits users were seen as hopeful of the company’s positive guidance for the next quarter.<stembedurl>https://stocktwits.com/45IQ/message/591848394</stembedurl>“We are confident in the long-term growth of our optimized LungFit PH system and have received positive feedback from new and existing customers as they realize the clinical benefits the system provides by offering on-demand, ambient air-generated NO compared to legacy cylinder NO systems,” Steve Lisi, Chairman and CEO Beyond Air, said in August.In October, Beyond Air entered a strategic partnership with Healthcare Links, a renowned healthcare advisory and contracting firm, to expand access to Beyond Air's LungFit PH system by streamlining entry into Group Purchasing Organizations, or GPOs, and Integrated Delivery Networks, IDNs, across the US, The Fly <a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=XAIR">reported.</a>XAIR stock is down 73.93% year-to-date, but Stocktwits sentiment suggests retail remains optimistic about the company’s long-term turnaround potential.For updates and corrections, email newsroom@stocktwits.com&nbsp;&nbsp;

Analysts estimate Beyond Air will report losses per share of $0.28.| Source: Pixabay

Beyond Air Stock Rises Ahead Of Earnings: Retail Bullish

Retail sentiment on the company inched up on Monday, rising to ‘bullish’ (67/100) from ‘neutral’ (46/100) a day ago. 

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.68	--	--	N/A
Q2 '25	-$0.77	-$1.25	-61.64%	MISSED
Q1 '25	-$1.23	-$1.53	-24.59%	MISSED
Q4 '24	-$0.12	-$1.80	-1375.41%	MISSED
Q3 '24	-$0.16	-$0.15	5.90%	BEAT

XAIR
Beyond Air Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest XAIR News

XAIRBeyond Air Inc